エピソード

  • Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian

    Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
    2026/02/25
    In this episode of Power to the Patients, host Brandon Li sits down with Dr. Lara Shirikjian, Medical Director at CenExel, to explore why operational excellence, not just innovation, drives progress in psychiatric drug development. Drawing on more than two decades of experience in schizophrenia and CNS research, Dr. Shirikjian explains how protocol mastery, direct sponsor communication, and community trust are essential to running high-performing research sites and advancing meaningful psychiatric treatments.
    続きを読む 一部表示
    40 分
  • Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health

    Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health
    2026/02/18
    In this episode of Power to the Patients, Brandon Li and Sonia Prashar, Founder and CEO of AIM Trials, sit down to discuss how hybrid and decentralized clinical trial models are reshaping mental health research. Sonia shares how her personal experience with postpartum depression inspired a mission to reduce patient burden, expand access, and improve data quality, while challenging stigma and outdated research assumptions along the way.
    続きを読む 一部表示
    34 分
  • The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients

    The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients
    2026/02/11
    In this episode of Power to the Patients, Brandon Li sits down with Dr. Craig Erickson, Research Director and Research Endowed Professor at Cincinnati Children’s, to explore how synaptic restoration is revolutionizing treatment for Fragile X, autism, ALS, Alzheimer's, and schizophrenia. From his decades of clinical experience and pioneering work at Spinogenix, Dr. Erickson shares the science behind restoring brain connectivity, the bold early results that surprised even experts, and why this approach could transform outcomes for patients with devastating neurological disorders.
    続きを読む 一部表示
    39 分
  • Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs

    Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs
    2026/02/04
    In this episode of Power to the Patients, Brandon Li sits down with Dr. Laxminarayan Bhat, Founder and CEO of Reviva Pharmaceuticals, to explore groundbreaking developments in schizophrenia treatment. Dr. Bhat shares insights on his company's innovative drug that shows promising results with fewer side effects and better patient adherence than existing treatments. Discover how their unique approach to targeting serotonin-dopamine signaling, combined with reduced off-target effects, could transform the lives of millions living with schizophrenia. Learn about the challenges and triumphs of developing psychiatric medications, the role of biomarkers in treatment, and the future of precision psychiatry.
    続きを読む 一部表示
    32 分
  • The 20-Year Industry Secret: Redefining Neurodegenerative Treatment

    The 20-Year Industry Secret: Redefining Neurodegenerative Treatment
    2026/01/09
    In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis, and reveals why shorter clinical trials may be missing the bigger picture.
    続きを読む 一部表示
    53 分
  • One Mechanism, Three Conditions: A New Direction in Neurological Treatment

    One Mechanism, Three Conditions: A New Direction in Neurological Treatment
    2025/12/03
    What if inflammation was the key to unlocking treatments for Alzheimer's, Parkinson's, and Long COVID? In this episode of Power to the Patients, Brandon Li sits down with Cuong Do, CEO of BioVie, to explore the fascinating intersection of these seemingly unrelated conditions. From diving into medical research at the age of 14 to leading groundbreaking clinical trials, Cuong shares invaluable insights on biotech innovation, trial design, and navigating today's challenging funding landscape. Tune in to discover how a single molecule's unique ability to cross the blood-brain barrier could potentially transform treatment for millions of patients.
    続きを読む 一部表示
    35 分
  • Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution

    Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution
    2025/11/12
    In this episode of Power to the Patients, Brandon Li sits down with Dr. Chris Witowski, CEO and Co-Founder of Psilera, to explore the fascinating intersection of psychedelics and neurodegeneration. Discover how non-hallucinogenic compounds could revolutionize treatments for conditions like frontotemporal dementia, why traditional psychedelics may have overlooked neurodegenerative applications, and the future of neuroplasticity-based therapies. From biomarker development to innovative drug delivery systems, this conversation offers deep insights into an emerging frontier in neuroscience that could transform patient care beyond traditional psychiatric applications.
    続きを読む 一部表示
    42 分
  • Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo

    Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
    2025/11/05
    In this episode of Power to the Patients, Brandon Li and Dr. Palumbo, Chief Medical Officer at BioVie Pharma, explore the evolving landscape of neuroscience research, the critical differences between big pharma and biotech approaches, and promising new pathways for treating conditions like Parkinson's and Alzheimer's. Whether you're a researcher, clinician, or industry professional, this conversation offers a fascinating look at how inflammation-focused treatments and systems biology could revolutionize neurological disease treatment.
    続きを読む 一部表示
    40 分